Figure 1
![Data obtained from Cohen, J. et al., 2020 [31]. BNP, B-type natriuretic peptide; MMP9, matrix metalloproteinase 9; CKD, chronic kidney disease; TIMP-4, tissue inhibitor of metalloproteinase 4; HF, heart failure; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.](https://port.silverchair-cdn.com/port/content_public/journal/clinsci/135/19/10.1042_cs20210127/1/cs-2021-0127ci001.png?Expires=1716272698&Signature=Ji~iKQ4pk5cXhgBqj6VxjfTCwascgqfY8SlCYtJwmxMhBMBEYQ26HelJMym5CcQzuG0NAxYSgxwSEHJxxVPf5mRqWHtXYwxOlmmFQVngMhi9d5fHuTB15jct5d4aChHHlgagkhxvdf2yYuw7bTVAkTY7tyxm3EIxrGaA39ER6oEJtsxUaCTfvg~7p2krciVdKkyPyIgVTZFA3P2Jup6n0Cnp3xvhuZo8D8e90pWRnuk8-UOTPGj4msxHeY~yfyGdED2Kua8QyeCEQdgiGcF13XRpOgaRMSgCzrkYh9TyFIJIaxwOFMJVqmpfe3igTpP2WxeMTGGy2guPZM0q8mRaPA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
The three phenogroups of heart failure with preserved ejection fraction
Data obtained from Cohen, J. et al., 2020 [31]. BNP, B-type natriuretic peptide; MMP9, matrix metalloproteinase 9; CKD, chronic kidney disease; TIMP-4, tissue inhibitor of metalloproteinase 4; HF, heart failure; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.